Business, energy, technology, markets and global industry news from Business News Today

antidepressant development

PharmaDeviceNews antidepressant development
Representative image of neuropsychiatry drug research, highlighting Draig Therapeutics’ DT-101 Phase 1 data, AMPA receptor potentiation and the search for new major depressive disorder treatments.
Pharma & Biotech

Draig Therapeutics DT-101 Phase 1 data put MEG biomarkers at the centre of depression trials

DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.

Read More
Enveric Biosciences EB-003 data deepen the case for non-hallucinogenic 5-HT2A antidepressants
Pharma & Biotech

What Enveric Biosciences’ EB-003 data reveal about separating benefit from hallucinations

Enveric Biosciences reports new EB-003 signaling data. Find out what this means for non-hallucinogenic antidepressant development and regulatory risk.

Read More
Pharma & Biotech

What Evecxia’s EVX-301 trial reveals about the future of serotonin-based psychiatry

Evecxia’s Phase 1b study uses direct brain biomarkers to validate serotonin synthesis amplification. Find out why this matters for antidepressant development.

Read More